UNIGE document Scientific Article
previous document  unige:39527  next document
add to browser collection
Title

Nouveaux traitements systémiques dans le cancer du pancréas avancé : implications sur la survie et considérations médicoéconomiques

Authors
Published in Revue médicale suisse. 2005, vol. 1, no. 24, p. 1616-20
Abstract More than 75% of patients with advanced pancreas cancer present at a later stage, when only palliative chemotherapy can be offered as the main treatment. Since introduced, gemcitabine has significantly improved the symptomatic impact of the disease, and this single-agent therapy still remains the gold-standard treatment aside of any exploratory protocol. Survival benefits have however been marginal, although a minority of long-term survivors now survives their disease up to two or three years. Results from a retrospective study conducted on cases followed by the oncosurgery service of the Geneva University Hospital from 1993 to 2003 support this observation, and show a trend towards a parallel increase in ambulatory-incurred costs.
Keywords AdultAgedAmbulatory Care/economicsAntineoplastic Combined Chemotherapy Protocols/economics/therapeutic useFemaleHumansLength of Stay/economics/statistics & numerical dataMaleMiddle AgedPancreatic Neoplasms/drug therapy/mortalityRetrospective StudiesSwitzerland
Identifiers
PMID: 16028707
Full text
Article (Author postprint) (400 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research group Groupe Roth Arnaud (oncologie) (285)
Citation
(ISO format)
MAZZURI, Sebastien, ROTH, Arnaud. Nouveaux traitements systémiques dans le cancer du pancréas avancé : implications sur la survie et considérations médicoéconomiques. In: Revue médicale suisse, 2005, vol. 1, n° 24, p. 1616-20. https://archive-ouverte.unige.ch/unige:39527

203 hits

0 download

Update

Deposited on : 2014-08-19

Export document
Format :
Citation style :